The use of high-dose of intravenous immunoglobulins (IVIGs) as immunomodulators for the treatment of COVID-19-affected individuals has shown promising results. IVIG reduced inflammation in these patients, who progressively restored respiratory function. However, little is known about how they may modulate immune responses in COVID-19 individuals. Here, we have analyzed the levels of 41 inflammatory biomarkers in plasma samples obtained at day 0 (pretreatment initiation), 3, 7, and 14 from five hospitalized COVID-19 patients treated with a 5-d course of 400 mg/kg/d of IVIG. The plasmatic levels of several cytokines (Tumor Necrosis Factor, IL-10, IL-5, and IL-7), chemokines (macrophage inflammatory protein-1α), growth/tissue repairing factors (hepatic growth factor), complement activation (C5a), and intestinal damage such as Fatty acid-binding protein 2 and LPS-binding protein showed a progressive decreasing trend during the next 2 wk after treatment initiation. This trend was not observed in IVIG-untreated COVID-19 patients. Thus, the administration of high-dose IVIG to hospitalized COVID-19 patients may improve their clinical evolution by modulating their hyperinflammatory and immunosuppressive status.

中文翻译：

---

高剂量静脉注射免疫球蛋白可能会调节 COVID-19 患者的炎症。


使用高剂量静脉注射免疫球蛋白 (IVIG) 作为免疫调节剂来治疗受 COVID-19 影响的个体已显示出有希望的结果。 IVIG 减轻了这些患者的炎症，使他们逐渐恢复了呼吸功能。然而，人们对它们如何调节 COVID-19 个体的免疫反应知之甚少。在这里，我们分析了 5 名接受 400 mg/kg/d 5 天疗程治疗的住院 COVID-19 患者在第 0 天（治疗开始）、第 3、7 和 14 天获得的血浆样本中 41 种炎症生物标志物的水平。 IVIG。多种细胞因子（肿瘤坏死因子、IL-10、IL-5 和 IL-7）、趋化因子（巨噬细胞炎症蛋白-1α）、生长/组织修复因子（肝生长因子）、补体激活 (C5a) 的血浆水平，并且在治疗开始后的接下来的2周内，脂肪酸结合蛋白2和LPS结合蛋白等肠道损伤呈现逐渐减少的趋势。在未经 IVIG 治疗的 COVID-19 患者中未观察到这种趋势。因此，对住院的 COVID-19 患者给予高剂量 IVIG 可能会通过调节其高炎症和免疫抑制状态来改善其临床进展。